Poland· PL-100410670
Mepsevii
A vestronidase alfa product containing vestronidase alfa, registered in Poland by Ultragenyx Germany GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Vestronidase alfa is registered in 10 of 19 countries.
Countries holding a registration under ATC A16AB18 (vestronidase alfa), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Vestronidase alfa · ATC A16AB18
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Vestronidase alfa
- Manufacturer
- Ultragenyx Germany GmbH
- Country
- Poland (PL)
- ATC code
- A16AB18
- ATC class
- Vestronidase alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vestronidase alfa in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumMepsevii 2 mg/mlUltragenyx Germany
- CzechiaMEPSEVIIUltragenyx Germany GmbH, Berlín
- FinlandMepseviiUltragenyx Germany GmbH
- IcelandMepseviiUltragenyx Germany GmbH
- SwedenMepsevii 2 mg/ml Koncentrat till infusionsvätska, lösningUltragenyx Germany GmbH
- SpainMEPSEVII 2 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONUltragenyx Germany Gmbh
- United KingdomMepsevii 10mg/5ml concentrate for solution for infusion vialsUltragenyx UK Ltd
- Japanベストロニダーゼ アルファ（遺伝子組換え）Ｕｌｔｒａｇｅｎｙｘ Ｊａｐａｎ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mepsevii
- Liechtenstein · Mepsevii
- Norway · Mepsevii
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/99b50d94-6299-48ca-8bf6-2fc248fc7b52 GET /v1/drugs/99b50d94-6299-48ca-8bf6-2fc248fc7b52?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "2 mg/ml",
"packaging": "Rpz ¦ EU/1/18/1301/001 ¦ 129621\n1 fiol.",
"substance": "Vestronidasum alfa 2 mg/ml",
"common_name": "Vestronidase alfa",
"pl_product_id": "100410670",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about vestronidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.